Cargando…

Atrophy of retinal vessels in neovascular age-related macular degeneration following long-term treatment with 20 intravitreal anti-VEGF injections

BACKGROUND: The study aimed to evaluate the changes in retinal vascular density in exudative age-related macular degeneration (AMD) after long-term anti-VEGF treatment using optical coherence tomography angiography (OCT-A), and to compare these changes with the vascular density in AMD treated for on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Resch, Miklós D., Balogh, Aniko, Kurth, Tilmann, Nagy, Zoltán Z., DeBuc, Delia Cabrera, Papp, András
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721060/ https://www.ncbi.nlm.nih.gov/pubmed/36471292 http://dx.doi.org/10.1186/s12886-022-02700-8

Ejemplares similares

Vascular density in age-related macular degeneration after one year of antiVEGF treatment with treat-and-extend and fixed regimens
por: Resch, Miklós D., et al.
Publicado: (2020)

Association between retinal vessel density and postoperative time after primary repair of rhegmatogenous retinal detachment
por: Resch, Miklós D., et al.
Publicado: (2021)

Reduced macular thickness and macular vessel density in early-treated adult patients with PKU
por: Serfozo, Csilla, et al.
Publicado: (2021)

The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
por: Han, Fangyuan, et al.
Publicado: (2022)

Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment
por: Bae, Ki Woong, et al.
Publicado: (2022)

Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration
por: Wen, Joanne C., et al.
Publicado: (2017)

Position of macula lutea and presence of proliferative vitreoretinopathy affect vitreous cytokine expression in rhegmatogenous retinal detachment
por: Balogh, Anikó, et al.
Publicado: (2020)

Results of Intravitreal Anti-VEGF Injection in Choroidal Neovascularization Caused by Pathologies Other Than Age-Related Macular Degeneration
por: Ozveren, Mehmet
Publicado: (2020)

Prevalence of Polypoidal Choroidal Vasculopathy in Eyes with Neovascular Age-Related Macular Degeneration Resistant to Intravitreal Anti-VEGF Treatment
por: Menteş, Jale, et al.
Publicado: (2022)

Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration
por: Gyenes, Andrea, et al.
Publicado: (2023)

The effect of incorrect scanning distance on boundary detection errors and macular thickness measurements by spectral domain optical coherence tomography: a cross sectional study
por: Varga, Boglárka Enikő, et al.
Publicado: (2014)

Foveal atrophy and macular hole formation following intravitreal ranibizumab with/without photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration
por: Rishi, Pukhraj, et al.
Publicado: (2011)

Suspension of Anti-VEGF Treatment Does Not Affect Expansion of RPE Atrophy in Neovascular Age-Related Macular Degeneration
por: Chujo, Shinichiro, et al.
Publicado: (2023)

Correlation between macular vessel density and number of intravitreal anti-VEGF agents for macular edema associated with branch retinal vein occlusion
por: Tomita, Ryo, et al.
Publicado: (2019)

Perforating scleral vessels adjacent to myopic choroidal neovascularization achieved a poor outcome after intravitreal anti-VEGF therapy
por: Yao, Wangjing, et al.
Publicado: (2022)

Outcome of 5-Year Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Using “Treat and Extend” Regimen
por: Jaki Mekjavic, Polona, et al.
Publicado: (2018)

Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema
por: Gelfman, Claire M., et al.
Publicado: (2021)

Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
por: Ali Said, Yasmin, et al.
Publicado: (2022)

Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration
por: Eng, Victor A., et al.
Publicado: (2020)

Immunological biomarkers of the vitreous responsible for proliferative alteration in the different forms of retinal detachment
por: Balogh, Anikó, et al.
Publicado: (2020)

Short‐time effect of intravitreal injections on retinal vascular oxygenation and vessel diameter in patients with diabetic macular oedema or neovascular age‐related macular degeneration
por: Mitsch, Christoph, et al.
Publicado: (2019)

Real-Time Automatic Segmentation of Optical Coherence Tomography Volume Data of the Macular Region
por: Tian, Jing, et al.
Publicado: (2015)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to traumatic choroidal rupture
por: Barth, T., et al.
Publicado: (2019)

Intraocular inflammatory cytokines in patients with neovascular age-related macular degeneration before and after initiation of intravitreal injection of anti-VEGF inhibitor
por: Sato, Tomohito, et al.
Publicado: (2018)

Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept
por: Adrean, Sean D., et al.
Publicado: (2022)

Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
por: Blazaki, Styliani, et al.
Publicado: (2023)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022)

Intravitreal Bevacizumab for Choroidal Neovascular Membrane in Macular Telangiectasia Type 2
por: Gonzalez Martinez, Orlando G, et al.
Publicado: (2023)

Intravitreal anti-VEGF monotherapy for thick submacular hemorrhage of less than 1 week duration secondary to neovascular age-related macular degeneration
por: Jain, Sachin, et al.
Publicado: (2013)

Efficacy Comparison of Intravitreal Anti-VEGF Therapy for Three Subtypes of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
por: Li, Jianqing, et al.
Publicado: (2018)

Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study
por: Corazza, Paolo, et al.
Publicado: (2021)

Clinical impact of COVID-19 on patients with choroidal neovascularization on intravitreal anti-VEGF therapy
por: Agorogiannis, Eleftherios I., et al.
Publicado: (2021)

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
por: García-Quintanilla, Laura, et al.
Publicado: (2019)

Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization
por: Ladas, Ioannis D, et al.
Publicado: (2009)

Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Non-Age-Related Macular Degeneration
por: Salehipour, Masoud, et al.
Publicado: (2010)

Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration
por: Hsia, Ning-Yi, et al.
Publicado: (2015)

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
por: Maggio, Emilia, et al.
Publicado: (2022)

Macular Hole following Intravitreal Bevacizumab Injection in Choroidal Neovascularization Caused by Age-Related Macular Degeneration
por: Moisseiev, Elad, et al.
Publicado: (2010)

The assessment of acute chorioretinal changes due to intensive physical exercise in young adults
por: Szalai, Irén, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9si9r5tu5o7knsg49g0k5h6a6c